CACNB3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL116362	0.45	11/20
SCHEMBL2585915	0.51	8/20
SCHEMBL619154	0.41	7/20
SCHEMBL620978	0.40	7/20
SCHEMBL621013	0.40	7/20
SCHEMBL621555	0.39	6/20
SCHEMBL617973	0.38	6/20
SCHEMBL1810921	0.51	5/20
SCHEMBL620400	0.44	5/20
SCHEMBL620595	0.44	5/20
SCHEMBL619405	0.43	5/20
SCHEMBL618375	0.37	5/20
Mirogabalin (SCHEMBL473853)	0.52	4/20
Mirogabalin (SCHEMBL1814663)	0.52	4/20
Mirogabalin (SCHEMBL1814664)	0.52	4/20
Mirogabalin (SCHEMBL1816421)	0.52	4/20
Mirogabalin (SCHEMBL1816422)	0.52	4/20
Mirogabalin (SCHEMBL1888044)	0.52	4/20
Mirogabalin (SCHEMBL1888046)	0.52	4/20
SCHEMBL2034740	0.46	4/20

Clinical trials — most relevant to CACNB3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination	PHASE4	UNKNOWN
Role of Intralipid in Management of Organophosphorus Poisoning	PHASE2/PHASE3	WITHDRAWN
4-Aminopyridine in Episodic Ataxia Type 2	PHASE2	WITHDRAWN
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain	PHASE2	COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients	PHASE2	WITHDRAWN
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome	PHASE1/PHASE2	NOT_YET_RECRUITING
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients	PHASE2	WITHDRAWN
Calcium Channel Blockade in Primary Aldosteronism	PHASE2	COMPLETED
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13)	nan	NOT_YET_RECRUITING
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development	nan	RECRUITING
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN
Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism	nan	COMPLETED
Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia	nan	COMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Evaluation of A Clinical Diagnostic Test for CRDS	nan	RECRUITING
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases	nan	UNKNOWN
Painful Channelopathies Study	nan	UNKNOWN
Artificial Intelligence for the Prioritization of Genetic Background in Brugada Syndrome	nan	COMPLETED
The Influence of Genetic Predisposition on Outcome After Catheter Ablation of Atrial Fibrillation.	nan	UNKNOWN
Pharmacogenetics and Cardiovascular Events	nan	COMPLETED
Verapamil in Supraclavicular Brachial Plexus Block	nan	UNKNOWN
Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies	nan	UNKNOWN
A Single Center Prospective Study in an Estimated 570 Patients Who Underwent Genetic Screening at UZ Brussel in the Context of a Primary Cardiac Arrhythmia. Patients Showing a Variant Class 3,4 or 5 in SCN4A or CLCN1 Will Undergo a Clinical and Electrophysiological Review After IC.	nan	NOT_YET_RECRUITING
5-HT3 Antagonists (Antiemetics) and Cardiac Safety	nan	COMPLETED
Characteristics of Idiopathic Familial Voice Disorders	nan	COMPLETED
iCorMicA - Stratified Medicine in Angina	nan	RECRUITING
MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CACNB3 binder may also engage these)

Protein	Name	Similarity
P54287	—	1.000	P54287 →
P54286	—	1.000	P54286 →
Q9MZL3	—	1.000	Q9MZL3 →
P54285	—	1.000	P54285 →
Q8R3Z5	—	0.995	Q8R3Z5 →
CACNB1	Voltage-dependent L-type calcium channel subu	0.989	landscape →
Q9MZL7	—	0.988	Q9MZL7 →
Q8CC27	—	0.986	Q8CC27 →
Q8VGC3	—	0.981	Q8VGC3 →
P54283	—	0.981	P54283 →
P19517	—	0.978	P19517 →
B4F7E7	—	0.972	B4F7E7 →
Q9MZL5	—	0.971	Q9MZL5 →
F1QWK4	—	0.966	F1QWK4 →
E2QY99	—	0.965	E2QY99 →
Q8JHF4	—	0.965	Q8JHF4 →
CACNB2	Voltage-dependent L-type calcium channel subunit beta-2	0.964	landscape →
Q9JLB2	—	0.961	Q9JLB2 →
P54288	—	0.961	P54288 →
Q92796	—	0.960	Q92796 →
P70483	—	0.959	P70483 →
Q62936	—	0.958	Q62936 →
Q6R005	—	0.957	Q6R005 →
Q9R0Z9	—	0.957	Q9R0Z9 →
Q5RDQ2	—	0.956	Q5RDQ2 →
Q9BTC8	—	0.956	Q9BTC8 →
Q924K8	—	0.956	Q924K8 →
Q5PYH7	—	0.956	Q5PYH7 →
F1MF74	—	0.955	F1MF74 →
Q8BML1	—	0.955	Q8BML1 →